CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade TransMedics Group, Inc. - TMDX CFD

    74.53
    0.5%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.36
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Transmedics Group Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 74.53
    Open* 74.8
    1-Year Change* 16.95%
    Day's Range* 74.16 - 75.02
    52 wk Range 36.42-99.63
    Average Volume (10 days) 960.86K
    Average Volume (3 months) 19.57M
    Market Cap 2.22B
    P/E Ratio -100.00K
    Shares Outstanding 32.65M
    Revenue 191.82M
    EPS -1.10
    Dividend (Yield %) N/A
    Beta 1.93
    Next Earnings Date Feb 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 74.53 0.60 0.81% 73.93 75.16 72.70
    Nov 30, 2023 75.60 2.17 2.96% 73.43 76.36 71.93
    Nov 29, 2023 72.78 1.25 1.75% 71.53 75.12 71.53
    Nov 28, 2023 70.23 1.17 1.69% 69.06 70.68 67.68
    Nov 27, 2023 70.23 0.85 1.23% 69.38 70.72 68.51
    Nov 24, 2023 70.07 2.64 3.92% 67.43 71.18 67.43
    Nov 22, 2023 68.87 0.90 1.32% 67.97 70.16 67.87
    Nov 21, 2023 67.81 -1.37 -1.98% 69.18 70.75 66.71
    Nov 20, 2023 69.77 1.64 2.41% 68.13 70.12 67.27
    Nov 17, 2023 68.63 1.69 2.52% 66.94 69.19 66.69
    Nov 16, 2023 66.68 1.44 2.21% 65.24 67.30 63.83
    Nov 15, 2023 65.51 0.74 1.14% 64.77 67.36 64.75
    Nov 14, 2023 64.73 2.91 4.71% 61.82 66.27 61.70
    Nov 13, 2023 59.55 1.41 2.43% 58.14 61.42 56.76
    Nov 10, 2023 57.31 -1.13 -1.93% 58.44 59.21 55.21
    Nov 9, 2023 58.14 -3.12 -5.09% 61.26 65.51 57.24
    Nov 8, 2023 61.15 0.61 1.01% 60.54 62.81 58.82
    Nov 7, 2023 60.70 3.77 6.62% 56.93 68.05 56.69
    Nov 6, 2023 40.16 -2.74 -6.39% 42.90 43.13 39.97
    Nov 3, 2023 42.57 2.06 5.09% 40.51 43.56 40.45

    TransMedics Group, Inc. Events

    Time (UTC) Country Event
    Tuesday, February 20, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Transmedics Group Inc Earnings Release
    Q4 2023 Transmedics Group Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 93.459 30.262 25.639 23.604 13.017
    Revenue 93.459 30.262 25.639 23.604 13.017
    Cost of Revenue, Total 28.187 9.103 9.004 9.741 7.283
    Gross Profit 65.272 21.159 16.635 13.863 5.734
    Total Operating Expense 124.296 69.69 52.023 53.207 33.254
    Selling/General/Admin. Expenses, Total 69.897 38.283 24.188 23.596 12.315
    Research & Development 26.812 22.304 18.831 19.87 13.656
    Operating Income -30.837 -39.428 -26.384 -29.603 -20.237
    Interest Income (Expense), Net Non-Operating -5.328 -4.751 -2.332 -3.563 -2.933
    Other, Net 0 -0.341 -0.545
    Net Income Before Taxes -36.165 -44.179 -28.716 -33.507 -23.715
    Net Income After Taxes -36.231 -44.215 -28.748 -33.547 -23.756
    Net Income Before Extra. Items -36.231 -44.215 -28.748 -33.547 -23.756
    Net Income -36.231 -44.215 -28.748 -33.547 -23.756
    Income Available to Common Excl. Extra. Items -36.231 -44.215 -28.748 -33.547 -23.756
    Income Available to Common Incl. Extra. Items -36.231 -44.215 -28.748 -33.547 -23.756
    Diluted Net Income -36.231 -44.215 -28.748 -33.547 -23.756
    Diluted Weighted Average Shares 29.5566 27.6168 24.7028 14.2048 20.2361
    Diluted EPS Excluding Extraordinary Items -1.22582 -1.60102 -1.16376 -2.36167 -1.17394
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -1.23901 -1.60102 -1.16376 -2.36167 -1.17394
    Unusual Expense (Income) -0.6
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 52.465 41.554 31.375 25.683 20.521
    Revenue 52.465 41.554 31.375 25.683 20.521
    Cost of Revenue, Total 15.724 12.788 10.672 7.568 6.171
    Gross Profit 36.741 28.766 20.703 18.115 14.35
    Total Operating Expense 53.371 43.643 38.154 30.627 30.266
    Selling/General/Admin. Expenses, Total 29.356 24.984 21.726 16.851 17.381
    Research & Development 8.291 5.871 5.756 6.808 6.714
    Operating Income -0.906 -2.089 -6.779 -4.944 -9.745
    Interest Income (Expense), Net Non-Operating -0.074 -0.536 0.078 -2.463 -1.756
    Net Income Before Taxes -0.98 -2.625 -6.701 -7.407 -11.501
    Net Income After Taxes -1.001 -2.636 -6.72 -7.426 -11.523
    Net Income Before Extra. Items -1.001 -2.636 -6.72 -7.426 -11.523
    Net Income -1.001 -2.636 -6.72 -7.426 -11.523
    Income Available to Common Excl. Extra. Items -1.001 -2.636 -6.72 -7.426 -11.523
    Income Available to Common Incl. Extra. Items -1.001 -2.636 -6.72 -7.426 -11.523
    Diluted Net Income -1.001 -2.636 -6.72 -7.426 -11.523
    Diluted Weighted Average Shares 32.5453 32.2603 32.0376 30.2299 27.9836
    Diluted EPS Excluding Extraordinary Items -0.03076 -0.08171 -0.20975 -0.24565 -0.41178
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS -0.03076 -0.08171 -0.20975 -0.25855 -0.41178
    Unusual Expense (Income) -0.6
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 252.294 118.705 146.766 100.001 34.794
    Cash and Short Term Investments 201.182 92.452 125.642 80.688 20.241
    Cash & Equivalents 201.182 25.58 24.581 20.092 20.241
    Short Term Investments 0 66.872 101.061 60.596 0
    Total Receivables, Net 27.611 5.934 6.864 6.559 3.438
    Accounts Receivable - Trade, Net 27.611 5.934 6.864 6.559 3.438
    Total Inventory 20.605 14.859 11.934 11.216 9.277
    Prepaid Expenses 2.896 5.46 2.326 1.538 1.838
    Total Assets 277.147 134.893 152.026 105.299 42.157
    Property/Plant/Equipment, Total - Net 24.353 15.688 4.754 4.792 3.474
    Property/Plant/Equipment, Total - Gross 37.482 25.423 12.781 11.139 8.611
    Accumulated Depreciation, Total -13.129 -9.735 -8.027 -6.347 -5.137
    Other Long Term Assets, Total 0.5 0.5 0.506 0.506 3.889
    Total Current Liabilities 23.661 23.238 11.879 16.115 12.553
    Accounts Payable 3.341 6.651 1.206 7.247 4.72
    Accrued Expenses 20.079 16.337 10.317 8.332 7.178
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0
    Other Current Liabilities, Total 0.241 0.25 0.356 0.536 0.655
    Total Liabilities 89.772 67.039 48.135 50.65 47.88
    Total Long Term Debt 58.696 35.197 34.657 34.146 33.67
    Long Term Debt 58.696 35.197 34.657 34.146 33.67
    Other Liabilities, Total 7.415 8.604 1.599 0.389 1.657
    Total Equity 187.375 67.854 103.891 54.649 -5.723
    Preferred Stock - Non Redeemable, Net 186.519
    Common Stock 666.277 510.488 502.217 424.134 0.001
    Additional Paid-In Capital 0 143.794
    Retained Earnings (Accumulated Deficit) -478.677 -442.446 -398.231 -369.483 -335.936
    Other Equity, Total -0.225 -0.188 -0.095 -0.002 -0.101
    Total Liabilities & Shareholders’ Equity 277.147 134.893 152.026 105.299 42.157
    Total Common Shares Outstanding 32.1414 27.7916 27.1753 21.1845 20.2361
    Redeemable Preferred Stock 0 0 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 536.724 662.655 261.73 252.294 250.586
    Cash and Short Term Investments 427.11 582.21 195.375 201.182 204.462
    Cash & Equivalents 427.11 582.21 195.375 201.182 204.462
    Short Term Investments 0 0
    Total Receivables, Net 60.654 47.524 38.62 27.611 22.035
    Accounts Receivable - Trade, Net 60.654 47.524 38.62 27.611 22.035
    Total Inventory 39.365 30.545 23.961 20.605 18.575
    Prepaid Expenses 9.595 2.376 3.774 2.896 5.514
    Total Assets 689.227 690.358 287.088 277.147 274.873
    Property/Plant/Equipment, Total - Net 137.865 26.894 24.1 24.353 23.787
    Other Long Term Assets, Total 0.56 0.809 1.258 0.5 0.5
    Total Current Liabilities 49.101 32.017 28.635 23.661 20.689
    Accounts Payable 12.836 7.031 4.329 3.341 3.08
    Accrued Expenses 33.636 24.742 24.062 20.079 17.383
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.629 0.244 0.244 0.241 0.226
    Total Liabilities 562.767 545.145 94.463 89.772 87.016
    Total Long Term Debt 505.434 504.669 58.802 58.696 58.54
    Long Term Debt 505.434 504.669 58.802 58.696 58.54
    Other Liabilities, Total 8.232 8.459 7.026 7.415 7.787
    Total Equity 126.46 145.213 192.625 187.375 187.857
    Common Stock 634.458 627.747 674.156 666.277 660.061
    Retained Earnings (Accumulated Deficit) -507.736 -482.314 -481.313 -478.677 -471.957
    Other Equity, Total -0.262 -0.22 -0.218 -0.225 -0.247
    Total Liabilities & Shareholders’ Equity 689.227 690.358 287.088 277.147 274.873
    Total Common Shares Outstanding 32.6421 32.5829 32.534 32.1414 31.934
    Redeemable Preferred Stock 0 0 0 0 0
    Property/Plant/Equipment, Total - Gross 155.521
    Accumulated Depreciation, Total -17.656
    Goodwill, Net 11.673
    Intangibles, Net 2.405
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -36.231 -44.215 -28.748 -33.547 -23.756
    Cash From Operating Activities -45.817 -28.864 -30.265 -32.286 -25.984
    Cash From Operating Activities 3.478 1.817 1.577 1.222 0.769
    Non-Cash Items 13.695 10.531 2.494 1.665 1.33
    Cash Interest Paid 3.26 3.334 3.475 3.877 2.401
    Changes in Working Capital -26.759 3.003 -5.588 -1.626 -4.327
    Cash From Investing Activities 54.513 29.267 -41.598 -60.501 12.307
    Capital Expenditures -11.907 -3.519 -0.455 -0.165 -0.418
    Other Investing Cash Flow Items, Total 66.42 32.786 -41.143 -60.336 12.725
    Cash From Financing Activities 167.927 1.393 75.549 92.723 22.064
    Financing Cash Flow Items 0 -0.705 92.521 -2.342
    Issuance (Retirement) of Stock, Net 145.468 1.393 76.254 0.202 0.046
    Issuance (Retirement) of Debt, Net 22.459 0 0 24.36
    Foreign Exchange Effects -1.021 -0.797 0.803 -0.085 -0.082
    Net Change in Cash 175.602 0.999 4.489 -0.149 8.305
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -2.636 -36.231 -29.511 -22.085 -10.562
    Cash From Operating Activities -8.661 -45.817 -41.782 -27.5 -18.406
    Cash From Operating Activities 1.287 3.478 2.193 1.302 0.507
    Non-Cash Items 4.081 13.695 10.967 6.659 3.067
    Changes in Working Capital -11.393 -26.759 -25.431 -13.376 -11.418
    Cash From Investing Activities -0.927 54.513 57.277 32.529 10.514
    Capital Expenditures -0.927 -11.907 -9.143 -6.213 -1.953
    Other Investing Cash Flow Items, Total 0 66.42 66.42 38.742 12.467
    Cash From Financing Activities 3.958 167.927 164.862 0.642 0.405
    Issuance (Retirement) of Stock, Net 3.958 145.468 142.403 0.642 0.405
    Foreign Exchange Effects 0.073 -1.021 -1.475 -0.865 -0.196
    Net Change in Cash -5.557 175.602 178.882 4.806 -7.683
    Issuance (Retirement) of Debt, Net 22.459 22.459
    Financing Cash Flow Items
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Fidelity Management & Research Company LLC Investment Advisor 9.1178 2975189 -268529 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.3363 2067575 50383 2023-06-30 LOW
    Lord, Abbett & Co. LLC Investment Advisor 5.7301 1869739 15656 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.4496 1778230 65739 2023-06-30 LOW
    Macquarie Investment Management Investment Advisor 5.192 1694166 -51191 2023-06-30 LOW
    Fred Alger Management, LLC Investment Advisor/Hedge Fund 5.0551 1649508 505869 2023-06-30 MED
    Allspring Global Investments, LLC Investment Advisor/Hedge Fund 3.8971 1271643 -22787 2023-09-30 LOW
    Invesco Advisers, Inc. Investment Advisor 3.8882 1268741 786409 2023-06-30 LOW
    Driehaus Capital Management, LLC Investment Advisor/Hedge Fund 3.5618 1162214 90023 2023-06-30 MED
    Sandhill Investment Management Investment Advisor 2.4911 812844 -174773 2023-06-30 LOW
    Emerald Advisers LLC Investment Advisor 2.4495 799293 8738 2023-09-30 MED
    Credit Suisse Funds AG Investment Advisor/Hedge Fund 2.4127 787268 -34732 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.3939 781144 40822 2023-06-30 LOW
    Summit Partners Public Asset Management, LLC Hedge Fund 2.0586 671716 -234452 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9695 642651 41936 2023-06-30 LOW
    Bellevue Asset Management AG Investment Advisor 1.8774 612613 -16871 2023-06-30 LOW
    Mellon Investments Corporation Investment Advisor/Hedge Fund 1.6998 554650 309024 2023-09-30 LOW
    Hassanein (Waleed H) Individual Investor 1.5074 491859 -7500 2023-09-01 LOW
    Next Century Growth Investors, LLC Investment Advisor 1.3575 442942 -35145 2023-06-30 LOW
    Ophir Asset Management Pty Ltd Investment Advisor 1.2821 418366 172949 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    TransMedics Group, Inc. Company profile

    About TransMedics Group Inc

    TransMedics Group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Heart EXPAND Trial, OCS Heart EXPAND Continued Access Protocol, or CAP, Trial and OCS Heart PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, TransMedics Group Inc revenues increased 18% to $30.3M. Net loss increased 54% to $44.2M. Revenues reflect OCS Lung net revenue segment increase of 72% to $10.7M, OCS Heart net revenue segment increase of 25% to $17.7M, United States segment increase of 14% to $21.9M, All other countries segment increase of 31% to $8.4M.

    Industry: Advanced Medical Equipment & Technology (NEC)

    200 Minuteman Road
    ANDOVER
    MASSACHUSETTS 01810
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    74.69 Price
    -0.380% 1D Chg, %
    Long position overnight fee -0.0137%
    Short position overnight fee -0.0082%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    2,024.77 Price
    -1.680% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    15,719.80 Price
    -1.630% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    41,324.40 Price
    +4.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading